Further, in a recent clinical trial (Hurvitz et al., 2020), BC patients were randomized to receive three distinct anti-HER2 treatments (trastuzumab, lapatinib, trastuzumab + lapatinib) followed by six cycles of standard combination chemotherapy along with the same anti-HER2 therapy. Here, ERBB2 is linked to breast cancer.